IL6 and ovarian cancer: These activated BM-MSCs subsequently increase secretion of interleukin-6 (IL-6), interleukin-8 (IL-8), and vascular endothelial growth factor A (VEGFA); promote angiogenesis in endothelial cells; and stimulate the migration of low-invasive ovarian cancer cells.